-+ 0.00%
-+ 0.00%
-+ 0.00%

How Investors Are Reacting To Nurix Therapeutics (NRIX) CMO Appointment

Simply Wall St·11/15/2026 02:34:49
Listen to the news
  • Nurix Therapeutics appointed Arati V. Rao, M.D. as chief medical officer and reported that partner Sanofi ended the SAR448272 STAT6 degrader program, removing associated milestone and royalty potential from that asset.
  • The new CMO's track record in late stage oncology and complex regulatory submissions aligns with Nurix Therapeutics' push to advance bexobrutideg and its degrader pipeline toward registrational trials and potential approvals.
  • We will look at how Nurix Therapeutics' investment narrative is affected by Dr. Rao's appointment as CMO and the evolving pipeline.

See how Nurix Therapeutics fits alongside other oncology and biotech stories by reviewing a curated 19 high quality undiscovered gems that may be flying under most investors' radar.

Nurix Therapeutics Investment Narrative Recap

To own Nurix Therapeutics, you need to believe bexobrutideg and the wider degrader platform can move from encouraging early data into successful registrational trials with partners like Roche, as framed in the analyst consensus Narrative on Simply Wall St. In the near term, the most important swing factor is continued clean execution around bexobrutideg clinical data and advancing toward later stage studies without major safety or efficacy surprises.

The biggest operational risk remains a high spend base against uneven collaboration income, highlighted by Q2 2026 revenue of US$9.0 million and a net loss of US$89.5 million when large license payments were absent. Dr. Rao’s appointment and Sanofi’s SAR448272 exit shift leadership and collaboration mix but do not fundamentally change that core risk reward equation right now.

The Sanofi decision to end development of STAT6 degrader SAR448272 matters because it removes up to about US$453 million in potential milestones plus royalties tied to that program, as well as an option for 50 50 U.S. economics described in the analyst consensus Narrative on Simply Wall St. For a business that has leaned on partnership proceeds, that is a clear hit to one potential non dilutive funding stream.

At the same time, Nurix Therapeutics still has other levers. The global bexobrutideg alliance with Roche, including a US$700 million upfront payment and up to US$2.3b in milestones, plus the IRAK4 partnership with Gilead, keeps multiple external funding and data catalysts on the table. For you as a shareholder, the focus stays on execution in those remaining partnered and wholly owned programs and whether clinical progress arrives fast enough to support ongoing R&D spend.

Nurix Therapeutics' narrative projects US$297.9 million revenue and US$47.6 million earnings by 2029, which sits against analyst assumptions of revenue decreasing 24.9% per year and an earnings decline of about US$247.3 million from US$294.9 million today.

Uncover why Nurix Therapeutics' fair value indicates a 123% potential upside to its current price, which could narrow quickly.

NasdaqGM:NRIX 1-Year Stock Price Chart
NasdaqGM:NRIX 1-Year Stock Price Chart

Exploring Other Perspectives

One alternate view that really clashes with the Nurix Therapeutics consensus is revenue risk. The most bearish analysts were assuming sales could trend toward only about US$39.9 million with earnings near US$7.3 million by 2029. That paints a far tougher setup, and Dr. Rao’s arrival plus the Sanofi change may push those expectations in either direction. You are seeing just how wide opinions can be, so it can help to compare several narratives before deciding where you land.

Explore 2 other Nurix Therapeutics fair value estimates, including one that suggests it could be worth just $33.50!

The Verdict Is Yours

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

Looking For More Investment Ideas Beyond Nurix Therapeutics?

Once you have a view on Nurix Therapeutics, it can help to cross check that thesis against other opportunities with different risk and income profiles.

  • For investors who care most about balance sheet strength and dependable fundamentals, scan through a focused list of solid balance sheet and fundamentals (24 results) that can help you narrow in on financially resilient businesses.
  • If capital preservation and a smoother ride matter to you, compare Nurix Therapeutics to a curated 30 resilient stocks with low risk scores that screens for companies with lower overall risk scores.
  • Income seekers can weigh Nurix Therapeutics against a targeted 6 dividend fortresses built around stocks that combine higher yields with a focus on stability.